This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steele, P. Articles by Vogel, R. Search for Related Content PubMed PubMed Citation Articles by Steele, P. Articles by Vogel, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Mitral Valve Prolapse Mobility Aids Hazardous Substances DB SULFINPYRAZONE

Circulation, Vol 60, 43-45, Copyright © 1979 by American Heart Association

ARTICLES

Platelet survival time and thromboembolism in patients with mitral valve prolapse

P Steele, H Weily, J Rainwater and R Vogel

Thromboembolism (TE) occurs in about 20% of patients with rheumatic mitral valve disease, and platelet survival time in these patients has correlated with TE. In patients with mitral valve prolapse, TE appears to occur very infrequently. Platelet survival (autologous labeling with chromium-51) was performed in 26 patients with mitral prolapse. Five patients had a history of stroke, as well as normal cerebrovascular arteriography and shortened platelet survival (average half-time +/- SEM 2.3 +/- 0.18 days; normal half-time 3.7 +/- 0.03 days; n = 26; p less than 0.01). Platelet survival was shortened in seven of 21 patients without TE (33%) (3.3 +/- 0.06 days; p less than 0.01 vs patients with TE). In 138 patients with rheumatic heart disease, platelet survival was shortened in 40 of 41 (98%) with a history of TE (2.3 +/- 0.08 days) and in 76 of 97 (78%) without TE (2.9 +/- 0.07 days; p less than 0.001 vs patients with TE). In patients with mitral prolapse, sulfinpyrazone increased platelet survival (2.4 +/- 0.16 to 2.7 +/- 0.19 days; n = 7; p less than 0.05). Our results suggest that platelet survival time is shortened in patients with mitral prolapse and rheumatic heart disease who have had TE. Of those without TE there is an increased frequency of shortened platelet survival in patients with rheumatic heart disease (78%) compared with those with mitral prolapse (33%), consistent with the infrequency of TE in mitral prolapse.

This article has been cited by other articles:

				E. Atalar, T. Aqil, K. Aytemir, I. Haznedarolu, N. Ozer, H. Kiliq, G. Kuru, S. Aksdyek, K. Ovtinq, S. Kes, et al. Diminished Global Fibrinolytic Capacity in Patients With Mitral Valve Prolapse Is Associated With Transient Ischemic Attacks Clinical and Applied Thrombosis/Hemostasis, January 1, 2002; 8(1): 41 - 44. [Abstract] [PDF]

				D. N. Salem, D. Hartnett Daudelin, H. J. Levine, S. G. Pauker, M. H. Eckman, and J. Riff Antithrombotic Therapy in Valvular Heart Disease Chest, January 1, 2001; 119(1_suppl): 207S - 219S. [Full Text] [PDF]

				H. D. Pedersen and J. Haggstrom Mitral valve prolapse in the dog: a model of mitral valve prolapse in man Cardiovasc Res, August 1, 2000; 47(2): 234 - 243. [Full Text] [PDF]

				M. B. Elam, M. J. Viar, T. E. Ratts, and C. M. Chesney Mitral Valve Prolapse in Women With Oral Contraceptive-Related Cerebrovascular Insufficiency: Associated Persistent Hypercoagulable State Arch Intern Med, January 1, 1986; 146(1): 73 - 77. [Abstract] [PDF]

				M. D. Cheitlin and R. C. Byrd The Click-Murmur Syndrome: A Clinical Problem in Diagnosis and Treatment JAMA, April 3, 1981; 245(13): 1357 - 1361. [Abstract] [PDF]